Eduardo Chang
Pulmonary Disease · The Woodlands, TXNPI 1689683153
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,735 of the $2,581 with a category attached, or 67.2%. Boehringer Ingelheim accounts for 72.0% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $2,337 and has fallen 99.1% since, to $20 in 2025. That places this record below the midpoint for pulmonary disease clinicians in TX, where the typical reported total is $1,976.
Across 45 payments — averaging $57.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2K
- Actelion Pharmaceuticals US, Inc.$143
- GSK$113
- Vapotherm Inc$110
- AstraZeneca$49
- Sunovion Pharmaceuticals Inc.$45
- plus $263 from 11 others
Across 17 payments — averaging $13,582 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$110K
- Astrazeneca UK Limited$67K
- AstraZeneca$54K
What the payments were for
- Speaking & faculty fees$1,73567%
- Food & beverage$83932%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 8 | $1,857 |
| Actelion Pharmaceuticals US, Inc. | 6 | $143 |
| GSK | 6 | $113 |
| Vapotherm Inc | 1 | $110 |
| AstraZeneca | 3 | $49 |
| Sunovion Pharmaceuticals Inc. | 6 | $45 |
| Merck | 3 | $44 |
| Sanofi | 2 | $33 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| Insmed, Inc. | 1 | $22 |
| Bayer | 1 | $22 |
| Grifols USA, LLC | 1 | $21 |
| Philips North America LLC | 1 | $20 |
| Electromed, Inc. | 1 | $20 |
| Gilead | 1 | $19 |
| Mylan Specialty L.p. | 1 | $16 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VAPOTHERM$110
How this compares
$2,581 in reported general payments places this provider in the 50th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in The Woodlands
- Jefy MathewThe Woodlands$318K
- Hammad QureshiThe Woodlands$84K
- Carlos Araujo PrezaThe Woodlands$76K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.